Showing posts with label popular press. Show all posts
Showing posts with label popular press. Show all posts

Monday, April 29, 2024

What The Economist doesn’t know about Psychiatry




It is always good to take an in depth look at articles in the popular press about psychiatry – because of the clear antipsychiatry bias. An article from the Economist was posted recently that seemed to get a positive reception in some areas.  In my estimation that reception was not warranted.  Interestingly the same principles of analyzing rhetoric can be applied to this article as the last post on this blog about “doing your own research.”  I will use the same concept by concept approach to examine this article that I used for that video.  At the time the article was posted I read it for free online and I hope it is still available so that any reader here can appreciate the full text.  The author was not listed.

1:  “But her local hospital, in Durham, England, was dismissive, suggesting she had anxiety, a mental-health condition, and that she was probably spending too much time watching videos on TikTok. Her mother describes the experience as “belittling”:

The author begins with a story about an autoimmune condition with many neuropsychiatric manifestations Pediatric Autoimmune-Neuropsychiatric Disorders Associated with Streptococcus (PANDAS).  This is a condition that is known within psychiatry for at least 25 years and is covered in major psychiatric textbooks.  The author proceeds to conflate the lack of a definitive diagnosis with deficiencies in psychiatry as if it is totally unknown in the field. It is not and the pathophysiology and neuropsychiatric manifestations are known and taught within the field.  Secondarily if I had to speculate on the medical specialists who are most likely to see people who are told by a physician or family member that “it’s all in your head” – they would be psychiatrists.  We tend to see more of these people than anybody else.  

2: And infections are one small piece of the puzzle. It is increasingly clear that inflammatory disorders and metabolic conditions can also have sizeable effects on mental health, though psychiatrists rarely look for them. All this is symptomatic of large problems in psychiatry.

Psychiatrists have always been more interested in inflammatory and infectious conditions affecting the brain than most other specialists.  Griesinger mentions inflammation as a mechanism affecting brain function in his 1845 text on psychiatry (2). It is highly likely that in any community - psychiatrists are making more of these diagnoses than primary care physicians because they know the manifestations and they need to rule out physical causes of mental illnesses to make a psychiatric diagnosis.  All psychiatrists are trained in making these diagnoses and not mistaking them for a mental illness occurring in a healthy person or a person with chronic illnesses not affecting brain function.  The only large problem here is the lack of knowledge about how psychiatrists are really trained.

Inflammatory disorders were used as treatments in the early 20th century.  In the pre-antibiotic era, 5-10% of asylum admissions were due to neurosyphilis and the associated psychiatric manifestations. Some of the early treatments were based on inducing fevers.  Austrian psychiatrist Julius Wagner-Jauregg was awarded the Nobel Prize in Medicine in 1927 for successful treatment of neurosyphilis by inoculating patients with malaria (2).  This work was replicated and additional agents were used to induce fevers by other investigators with similar results. In addition to the experimental results, this represented a sea change in the general attitude of treating psychosis in asylums where a previous biological treatment did not exist.  Subsequent innovations occurred when neuromodulation techniques were introduced in 1932 (5) and psychopharmacology in 1952 (6).

The early focus on gross neuropathology and transition to microanatomy led to the discovery of Alzheimer's Disease in 1906 and Binswanger's Disease a form of vascular dementia in 1894.  Both Alzheimer and Binswanger were considered psychiatrists - Alzheimer by his own designation and training and Binswanger was eventually appointed to head an asylum by age 30.  

As far as "rarely looking for them" goes the top 4 medical conditions I diagnosed in newly seen patients were probably Type 2 diabetes mellitus, hypothyroidism, hypertension, and atrial fibrillation. Any psychiatrist practicing in the last 30 years is aware that psychiatric disorders and pharmacological treatment can be associated with metabolic syndrome and the need to monitor for and prevent that condition. 

3:  Chronic conditions are poorly treated – apparently because they are not cured (paraphrased):

This is always an interesting rhetorical sleight-of-hand. In what other specialty is the expectation that chronic conditions will be cured? It does not take a lot of research to show that nobody is curing most diabetics, hypertensives, asthmatics, arthritics, or patients with a multitude of other chronic conditions. In fact most of these patients remain symptomatic even when they are treated. These are all conditions with clear cut laboratory tests and other disease markers.  These are all conditions where there is at least a speculative biological hypothesis of pathophysiology.  And yet – there is no expectation of cure and in fact much more expected mortality in other specialties. Why is psychiatry different?  It is not.

4:  Some people in the profession believe that biological psychiatry will lead to better characterizations of psychiatric problems including pathophysiology, drug treatment, and pharmacological targets/precision psychiatry (paraphrased):

It is obvious that biological psychiatrists have been at it for decades and much longer.  The journal Biological Psychiatry was founded in 1969 but biology has been a focus of psychiatric research dating back to mid-19th century when attempts were made to observe brain dissection correlates with behavior.  Griesinger (2) documents efforts by both Pinel and Esquirol to document brain abnormalities in severe mental illnesses. In his text he documents brain diseases leading to psychiatric care and associated organ dysfunction at autopsy in patients identified as having severe mental illness.

In the days of asylum care before biological psychiatry, delirious mania had a mortality rate of 75% (7).  That has essentially been reduced to zero with advances in modern biological psychiatry including electroconvulsive therapy and psychopharmacology.  There is probably no better example of advances due to biological psychiatry occurring over decades.

Like all other medical specialties, biological psychiatry is an active area of research with new journals like Molecular Psychiatry (1997) and Translational Psychiatry (2011) that are focused on the latest innovations in biological psychiatry and potential treatment applications.

5:  The DSM or the Bible of Psychiatry does not specify pathophysiology

Any time you see that the DSM is the “Bible of psychiatry” that is a red flag that indicates the author either lacks knowledge about the Bible or the DSM.  Here is a brief primer on the DSM to correct some misconceptions.  That primer emphasizes that the person using it (typically for diagnostic codes used for administrative purposes) is a trained professional and understands its limitations. Chief among those limitations includes ruling out medical causes of psychiatric symptomatology and understanding that it is not a guide for everyman to use for diagnosis and treatment.  Kendler (8) and others have taken it a step further to point out that it is an index of disorders and therefore a starting point – rather than an actual diagnostic guide.  In other words, meeting criteria for a diagnosis is not that same as having the diagnosis.  This is generally true of all codified systems of medical diagnosis.  An example would be the American College of Rheumatology classification criteria.  There is an extensive discussion of these classification criteria compared with diagnostic criteria and why the ACR currently endorses only the former (9).  It is basically the same discussion that Kendler uses in describing the indexing system – that there is sufficient heterogeneity in clinical presentations over time and geographical areas that every case needs to be individually considered. Here is the rationale from the leading text on systemic lupus erythematosus (SLE) (10):  

“The classification criteria do not contain a complete list of all the possible manifestations of lupus.  The manifestations of SLE often develop over a period of time, sometimes years, making the diagnosis more difficult at initial presentation. The diagnosis of lupus is made on clinical grounds, supported by laboratory data and depends highly on the physician’s knowledge and experience. (author’s emphasis)”

Despite the title, the DSM is not a guide to diagnosis or treatment. People who do not “meet criteria” are not automatically excluded from treatment consideration. Separate knowledge about psychopathology and diagnostic formulation is necessary. Speaking to the author’s concern about the lack of specific etiologies – even the skeletal classification and indexing framework of the DSM has chapters on clear medical, toxicological, and neurological causes of mental disorders.

The Economist dates psychiatry’s “Bible” back to 1952.  That would have been the DSM-I.  I encourage anyone who is interested to read the 6 page Forward to that document.  It started initially to standardize nomenclature. Each training program was using their own version of nomenclature as well as the military.  When trained psychiatrists went out to practice in the community – there was no standard nomenclature being used to described similar phenomenon and the requirements of military and civilian nomenclature were different. The secondary goal was to use this nomenclature to collect statistics that could be used to improve the necessary infrastructure and resources to treat these disorders.  All of this can be done without any specific reference to pathophysiology in both psychiatry and the rest of medicine.    

And here is a news flash from the DSM-5,  my estimate is that 69% of all of the diagnoses listed have a clear pathophysiology or medical test equivalent to any other branch of medicine.  Given the classification problems with all medical diagnoses that overall figure probably compares well with any other branch of medicine.   

Whatever your take away from this post, The Economist knows very little about psychiatry and medicine. But that should not be too surprising.  The tone and factual content clearly resemble much of what you see on the Internet and in the press about psychiatry. That does not make it any less wrong.  If you are really interested in what is going on in the field – I would recommend reading the general literature in the field or summaries about it. The popular press – newspapers and magazines – is clearly not up to the task.

6:  Attempts to find causal mechanisms for mental illnesses have failed (paraphrased):

News flash – that is true of every other complex disease as well as the medication used to treat them.  This post illustrates that fact with medication used to treat multiple sclerosis.  The table lists 18 FDA approved drugs – many of which modify the course of the illness but in every case the specific mechanism of action of the drug is unknown.

7:  Genetics has been a clinical “flop” (paraphrased):

It would probably be a good idea to get the opinion of an expert in psychiatric genetics.  The article seems to focus on the issue of polygenic risk analysis (PRA) and those studies generally have low effect sizes due to the number of genes studied.  Any commercial assessment of a genome will result in hundreds of these profiles – most of them for non-psychiatric illnesses. The example given above illustrates polygenic risk scores (PRS) when the small risk factors (both protective and potentially causative) are summed and compared to a standard sample so that 100% is highest percentile risk in the sample and 0% is the lowest. This is only one approach and there are major psychiatric initiatives in this space doing ongoing research. PRA/PRS is accepted science at this point but the widespread clinical utility is not known for practically all polygenic disorders.

Recent examples given by Kendler (11) in his commentary on whether psychiatric disorders are brain diseases points to the importance of genetics in psychiatry.  To this day there are endless debates, typically by people who are not trained to be psychiatrists that psychiatric disorders are somehow independent of brain substrate. In other words, even though it is widely acknowledged that a brain is required for mental life – there is no evidence at the molecular level that an alteration in brain function causes mental illness. Contrary to The Economist, Kendler states: “I use the most robust empirical findings in all of psychiatry—that genetic risk factors impact causally and substantially on liability to all major psychiatric disorders.”  He quotes the recent literature illustrating that risk variants for schizophrenia are located only in brain tissue.  Similar evidence is accumulating for bipolar disorder and major depression. This correlation of strongest known risk factors and brain substrate location is good evidence of specific genetic effects in the brain. Similar work is being done to identify signaling systems, proteins, and physiological processes underlying the DSM classifiers.  Once again, this is similar to the approaches being taken with all complex non-psychiatric diseases. 

8:  Biology is coming, whether psychiatry is ready or not:

When I saw this caption – it seemed like a joke.  Over the 40 years of my career there has been a constant battle based on the false dichotomy of biological psychiatrists and psychotherapy focused psychiatrists. That left out important additional identities including medical psychiatrists, neuropsychiatrists, and community psychiatrists. Practically all the criticism in the press has been that psychiatrists are too biological. I could probably write a book about this – but in this case suffice it to say that The Economist has not done much homework. The smattering of research projects listed in the last several paragraphs about immunology and metabolism ignores that this type of research has been going on for decades and gradually making progress. 

Every psychiatrist is trained in the biology of medicine and psychiatry - just like me.  We are willing to incorporate the latest research innovations and look forward to them. Biology comes as no surprise.

 

George Dawson, MD, DFAPA

 

 

 

References:

1:  “Many mental-health conditions have bodily triggers: Psychiatrists are at long last starting to connect the dots.:  April 24, 2024.  In the print edition this story is under the general heading "Psychiatry’s blind spots".  No author was listed for the online version that I read.

2:  Griesinger W: Die Pathologie und Therapie der Psychischen Krankheiten: für Aerzte und Studirende. (The pathology and therapy of mental illnesses, for doctors and students). Stuttgart, Germany, Verlagvon Adolph Krabbe, 1845  https://www.deutschestextarchiv.de/book/view/griesinger_psychische_1845?p=47

3:  Wagner-Jauregg J. The treatment of general paresis by inoculation of malaria. J Nerv Ment Dis. 1922;55:369–375. [Google Scholar] [Ref list]

4:  Tsay CJ. Julius Wagner-Jauregg and the legacy of malarial therapy for the treatment of general paresis of the insane. Yale J Biol Med. 2013 Jun 13;86(2):245-54. PMID: 23766744; PMCID: PMC3670443.

5:  Gazdag G, Ungvari GS. Electroconvulsive therapy: 80 years old and still going strong. World J Psychiatry. 2019 Jan 4;9(1):1-6. doi: 10.5498/wjp.v9.i1.1. PMID: 30631748; PMCID: PMC6323557.

6:  Ban TA. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat. 2007 Aug;3(4):495-500. PMID: 19300578; PMCID: PMC2655089.

7:  Bell, L., 1849. On a form of disease resembling some advanced stage of mania and fever.  Am. J. Insanity 6, 97–127. 

8:  Kendler KS. The Phenomenology of Major Depression and the Representativeness and Nature of DSM Criteria. Am J Psychiatry. 2016 Aug 1;173(8):771-80. doi: 10.1176/appi.ajp.2016.15121509. Epub 2016 May 3. PMID: 27138588.

9:  Aggarwal R, Ringold S, Khanna D, Neogi T, Johnson SR, Miller A, Brunner HI, Ogawa R, Felson D, Ogdie A, Aletaha D, Feldman BM. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015 Jul;67(7):891-7. doi: 10.1002/acr.22583. PMID: 25776731; PMCID: PMC4482786.

10:  Rudinskaya A, Reyes-Thomas J, Lahita R.  The clinical presentation of systemic lupus erythematosus and laboratory diagnosis. In: Lahita RG, Costenbader KH, Bucala R, Mani S, Khamashta MA.  Lahita’s Systemic Lupus Erythematosus. 6th ed.  London, England:  Elsevier, 2021: 316.

11:  Kendler KS. Are Psychiatric Disorders Brain Diseases?-A New Look at an Old Question. JAMA Psychiatry. 2024 Apr 1;81(4):325-326. doi: 10.1001/jamapsychiatry.2024.0036. PMID: 38416478.

Sunday, March 25, 2012

Psychiatrists work for patients - not for pharmaceutical companies



That should be obvious by anybody reading this post but it clearly is not. I have already established that there is a disproportionate amount of criticism of psychiatry in the popular media compared with any other medical specialty. The most common assumption of most of those critics is that psychiatrists are easily influenced by pharmaceutical companies or thought leaders who are working for pharmaceutical companies. There are many reasons why that assumption is incorrect but today I want to deal with a more implicit assumption that is that there is a drug that is indicated and effective for every medical condition.

In the field of psychiatry this marketing strategy for pharmaceuticals became prominent with the biological psychiatry movement in the 1980s. Biological psychiatrists studied neuropsychopharmacology and it followed that they wanted to apply their pharmaceuticals to treat human conditions. At the popular level initiatives like National Depression Screening Day were heavily underwritten by pharmaceutical companies and the implicit connection was that you could be screened and be treated with a medication that would take care of your depression.

From the perspective of a pharmaceutical company this is marketing genius. You are essentially packaging a disease cure in a pill and suggesting that anyone with a diagnosis who takes it will be cured. The other aspects of marketing genius include the idea that you can be "screened" or minimally assessed and take the cure. We now have the diagnosis, treatment, and cure neatly packaged in a patent protected pill that the patient must take.  The role of the physician is completely minimized because the pharmaceutical company is essentially saying we have all the expertise that you need. The physician's role is further compromised by the pharmaceutical benefit manager saying that they know more about which pill to prescribe for particular condition than the physician does. That is an incredible amount of leverage in the health care system and like most political dimensions in healthcare it is completely inaccurate.

The pharmaceutical company perspective is also entirely alien to the way that psychiatrists are trained about how to evaluate and treat depression.  Physicians in general are taught a lot about human interaction as early as the first year in medical school and that training intensifies during psychiatric residency. The competencies required to assess and treat depression are well described in the APA guidelines that are available online.  A review of the table of contents of this document illustrates the general competencies required to treat depression. Reading through the text of the psychopharmacology section is a good indication of the complexity of treating depression with medications especially attending to side effects and complications of treatment and decisions on when to start, stop, and modify treatment. Those sections also show that psychopharmacology is not the simple act that is portrayed in the media. It actually takes a lot of technical skill and experience.  There really is no simple screening procedure leading to a medication that is uniformly curative and safe for a specific person.

The marketing aspects of these medications often create the illusion that self-diagnosis or diagnosis by nonexperts is sufficient and possible. Some people end up going to the website of a pharmaceutical company and taking a very crude screening evaluation and concluding that they have bipolar disorder. In the past year, I was contacted by an employer who was concerned about the fact that her employee had seen a nonpsychiatrist and within 20 minutes was diagnosed with bipolar disorder and treated with a mood stabilizer, an antidepressant, and an antipsychotic medication. Her concern was that the employee in question could no longer function at work and there was no follow-up scheduled with the non-psychiatrist who had prescribed medication.  Managed care approaches screening patients in primary care settings increase the likelihood that these situations will occur.

The current anti-psychiatry industry prefers to have the public believe that psychiatrists and their professional organization are in active collusion with the pharmaceutical industry to prescribe the most expensive medications.  In the case of the approximately 30 antidepressants out there, most are generic and can be easily purchased out-of-pocket.  Only the myth that medications treat depression rather than psychiatrists keeps that line of rhetoric going.

George Dawson, MD

American Psychiatric Association.  Practice Guideline for the Treatment ofPatients With Major Depressive Disorder, Third Edition. 2010

Tuesday, March 13, 2012

NYTimes Tells You How to Rate Your Doctor

The New York Times has a feature (see first reference) that discusses why the number of Internet reviews of physicians is sparse and the quality is poor.  The main contention is that people are too intimidated to rank physicians. The author ignores the profit motive of all the sites as a potential conflict of interest and leaps to the conclusion that the AMA speaks for most physicians even though only about 29% of physicians are members of the AMA.  He also describes physicians as "untouchable" when in fact at least 20% of physicians can be expected to be sued for malpractice during their lifetime and malpractice lawsuits have resulted in entire specialties migrating from a particular state. That is hardly what I would describe as "untouchable".  He is openly critical of the president of the AMA suggesting that anonymous, undocumented, and unverified reviews are probably not the best source for a physician recommendation.  He quickly invalidates "disproportionately positive reviews" on some websites is the product of an "unquestioning mindset".
The worst part of the article is leaping ahead to the Medicare initiative and their physician report card. Nevermind the fact that the risk adjustment concern by the AMA is legitimate.  Nevermind the fact that there is really no valid way to compare physicians at this point in time.  Nevermind the fact that there are political interests at play in particular the managed-care industry and how they can potentially game the system in favor of their principles. The author basically is encouraging people to go full speed ahead.
The result of that experiment is fairly predictable. The only thing I am hoping is that Google will come up with a way to prioritize the relevant information about physicians such as where they really practice and how to get a hold of them instead of the pages and pages that you currently encounter when you are trying to find a physician.
The AMA doesn't give much better advice in their recent edition of the amednews.  In a piece entitled "Physician rating website reveals formula for good reviews", their first suggestion was to not have a patient waiiting for more than 15 minutes and no more than 10 minutes in the exam room.  I can't think of any practice where the physician has that kind of control over their schedule - even if they postpone all of the documentation and stay for several hours after the clinic closes to get it done.  The business experts observed:  "overall ratings were based on time in the waiting room and the exam room -- rather than perceived clinical quality".  Keep that in mind when you are looking at online ratings of physicians.
I would suggest an experiment of my own that I have conducted several times with a high degree of success.  Imagine that you have a serious medical condition that requires a high risk procedure and you want to find the best physician to help you.  Your search process will involve the Internet, but it does not involve looking at any of the ratings you find when you search on a physician's name.  What do you do?
I will come back and answer that at a later date and discuss how that needs to be modified when you are looking for a psychiatrist.
George Dawson, MD
Ron Lieber.  The Web Is Awash in Reviews, but Not for Doctors area Here's Why. New York Times March 9, 2012
Pamela Louis Dolan.  Physician rating website reveals formula for good reviews.  amednews. Feb. 27, 2012

Monday, February 27, 2012

Critical Article on the Efficacy of Psychiatric Medication


There is a seminal article in this month’s British Journal of Psychiatry by Leucht, Hierl, Kissling, Dold, and Davis.  The authors did some heavy lifting in the analysis of 6175 Medline abstracts and 1830 Cochrane reviews to eventually compare 94 meta-analyses of 48 drugs in 20 medical diseases and 33 meta-analyses of 16 drugs in 8 psychiatric disorders.  The authors have produced a graphic comparing the Standard mean difference of effect sizes between the general medicine drugs and the psychiatric drugs.  It is apparent from that graphic that the psychiatric drugs are well within the range of efficacies of the general medical drugs.

This is an outstanding study that merits reading on several levels.  The authors have used state of the art approaches to meta-analysis following suggested conventions.  They provide the summary of the studies reviewed and actual details of their calculations in the accompanying tables. (the document including references and PRISMA diagrams is 59 pages long.)  They have a comparison of standard criticisms of psychiatric drugs and illustrate how the criticisms are not fair and the toxicity considerations are often greater in the general medicine drugs than the psychiatric drugs. 

This paper should be read by all psychiatrists since it is an excellent illustration of an approach to large scale data analysis using modern statistical techniques.  It is a good example of the application of the discussion by Ghaemi of hypothesis testing statistics versus effect estimation.  The authors also have an awareness of the limitations of statistics that the detractors of psychiatric care seem to lack.  Their statements are qualified but they provide the appropriate context for decision making about these medications and the implication is that decision matrix is clearly squarely in the realm of other medical treatments in medicine.

From the standpoint of the media and the associated politics it will also be interesting to see if this article gets coverage relative to the articles that have been extremely critical of psychiatric drugs.  I can say that I have provided the link to the article by Davis, et al on the issue of antidepressant effectiveness to several journalists including the New York Times and it was ignored.  The press clearly only wants to tell the story against antidepressants and psychiatric medications.

Never let it be said that any aspect of psychiatric treatment gets objective coverage in the press.  That problem and the lack of investigation of that problem is so glaring at this point that the press lacks credibility in any discussion of psychiatric treatment.

George Dawson, MD

Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective:review of meta-analyses. Br J Psychiatry. 2012 Feb;200:97-106. PubMed PMID: 22297588

S. Nassir Ghaemi (2009) A Clinician’s Guide to Statistics and Epidemiology in Mental Health: Measuring Truth and Uncertainty.  Cambridge University Press, New York.

Davis JM, Giakas WJ, Qu J, Prasad P, Leucht S. Should we treat depression with drugs or psychological interventions? A reply to Ioannidis. Philos Ethics Humanit Med. 2011 May 10;6:8.
Seemuller F, Moller HJ, Dittmann S, Musil R. Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication? BMC Med. 2012 Feb 15;10(1):17. Free full text commentary on the main article from another journal    -      download the pdf.